Effective vaccination against long-term gammaherpesvirus latency.
about
Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2Interplay of Murine Gammaherpesvirus 68 with NF-kappaB Signaling of the HostEffective control of chronic gamma-herpesvirus infection by unconventional MHC Class Ia-independent CD8 T cells.Antibody-independent control of gamma-herpesvirus latency via B cell induction of anti-viral T cell responses.Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.Virus-encoded microRNAs facilitate gammaherpesvirus latency and pathogenesis in vivoDendritic cells loaded with tumor B cells elicit broad immunity against murine gammaherpesvirus 68 but fail to prevent long-term latencyActivation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin-deficient miceA gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge.Vaccination against a hit-and-run viral cancer.CD4 memory T cells divide poorly in response to antigen because of their cytokine profileMaintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes.Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infectionImportance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68Sheep-associated malignant catarrhal fever virus: prospects for vaccine development.The limits of protection by "memory" T cells in Ig-/- mice persistently infected with a gamma-herpesvirusNF-kappaB p50 plays distinct roles in the establishment and control of murine gammaherpesvirus 68 latency.Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection.Prospects of a novel vaccination strategy for human gamma-herpesviruses.KSHV targeted therapy: an update on inhibitors of viral lytic replication.Use of a virus-encoded enzymatic marker reveals that a stable fraction of memory B cells expresses latency-associated nuclear antigen throughout chronic gammaherpesvirus infection.T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics.An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infectionCritical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency.Immature and transitional B cells are latency reservoirs for a gammaherpesvirus.A replication-defective gammaherpesvirus efficiently establishes long-term latency in macrophages but not in B cells in vivo.
P2860
Q27318672-CBE3C1F4-42E2-494B-B096-C60EE771FD8CQ28080198-C1E56810-4DD3-4D83-8E6A-C25EEDE27909Q33245067-1013704E-E413-448D-818B-6D3756C60955Q33247469-A50D963A-5AAD-4ADD-9C78-1FA902A0609FQ33648926-8F5D948E-2B08-4924-A8D8-CE86CB067F32Q33709525-750EFDDA-0503-439D-9153-2A2DCFB0E279Q34055365-2BC9CCBB-F2BD-4B20-86ED-D0D8F2337260Q34059398-80D0F97A-6A4F-488C-8383-6B66D54CA9A6Q34142912-07866F39-2A52-4D7F-8F00-92F7BAFBEC51Q34302056-F58068D0-6912-4FDB-982A-41D78D0B1843Q34641583-2736615F-070D-4424-B29F-AC5BC4477B53Q34826020-E1070F4D-74B9-45C4-855A-CBB022AFB31EQ34976412-B2D45776-D3EF-4099-B6D5-14FACB8B231BQ35149326-CBC898F4-7198-4096-949E-2D7136A3D5ABQ35685590-6212E2D1-9037-486A-8817-2472DF11315FQ36383828-DBEE5F0B-C190-4D2B-A141-0CD75B2CF86BQ36604481-015DE809-AF20-49B0-8CA8-E2B83104B53DQ37192183-BC97459C-EB3B-4102-94FB-1EC02A939525Q37348174-31BE714A-20C9-48DF-930D-AA396BEA03DFQ37780705-CC55891C-D734-4752-8BDF-35DF88ABA58BQ38271135-6A79D5BC-2151-495B-B5B7-9F93692106CFQ39702331-78B448CD-7C7D-4065-B360-52359C1D7EE6Q39992518-0AFFF412-E960-4B39-8EE4-416611CA0204Q40909600-F44BF363-C2B2-4712-A723-EAA151965DC1Q40909739-33D64BF4-D124-4B18-A72E-F1D8B7895001Q41232435-B6646AEA-1DD8-45C1-8715-B29E3E5ECC94Q42407089-A6529D7A-059B-4814-8129-F00F8C51E6A1
P2860
Effective vaccination against long-term gammaherpesvirus latency.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Effective vaccination against long-term gammaherpesvirus latency.
@en
Effective vaccination against long-term gammaherpesvirus latency.
@nl
type
label
Effective vaccination against long-term gammaherpesvirus latency.
@en
Effective vaccination against long-term gammaherpesvirus latency.
@nl
prefLabel
Effective vaccination against long-term gammaherpesvirus latency.
@en
Effective vaccination against long-term gammaherpesvirus latency.
@nl
P2093
P2860
P1433
P1476
Effective vaccination against long-term gammaherpesvirus latency.
@en
P2093
J Scott McClellan
Samuel H Speck
Scott A Tibbetts
Shivaprakash Gangappa
P2860
P304
P356
10.1128/JVI.77.4.2522-2529.2003
P407
P577
2003-02-01T00:00:00Z